Gaudium IVF IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 44.26 | 48.15 | 70.96 |
| Expense | 25.95 | 31.52 | 45.54 |
| Profit (PAT) | 13.53 | 10.32 | 19.13 |
| Total Assets | 36.63 | 51.01 | 88.51 |
Promoters: Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 6,13,94,384 | 99.99% |
| Promoter Holding Post Issue | 7,27,86,884 | 71.30% |
Strengths & Risks
- Strongly subscribed — 7.3x overall (final).
- Revenue grew 47% in the latest reported year.
- Solid profit margin — 27.0%.
- Strong return on equity — 41%.
No major red flags in the available data.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India. The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes. The firm treats its patients in various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The firm offers various fertility services such as Vitro Fertilisation (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction. Its treatments are targeted towards both genders. Moreover, the firm also provides PCOD/PCOS, endometriosis, and special care for women in pregnancy with complex fertility issues. Gaudium IVF also offers treatments targeting male infertility, including advanced sperm retrieval procedures.
| Purpose | Amount (Cr) |
|---|---|
| Funding capital expenditure towards establishment of New IVF Centers of the Company | 50.00 |
| Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and | 20.00 |
| General Corporate Purpose | - |
Resources & Documents
Gaudium IVF & Women’s Health Ltd., B1/51,, Janak Puri,, B-1,, New Delhi, New Delhi, 110058
Gaudium IVF has set a price band of Rs 75–Rs 79 per share for an issue size of Rs 165 crore. The stock listed with a 5.06% gain versus its issue price on February 27, 2026.
Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India. The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes.
The issue is promoted by Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna with Sarthi Capital Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Funding capital expenditure towards establishment of New IVF Centers of the Company (Rs 50 crore) and Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and (Rs 20 crore).
Grey market is quoting a discount of Rs -4 (-5.1% over issue price), down Rs 4 from the previous session. Final subscription data records overall subscription at 7.27x, retail at 7.60x, QIB at 1.62x, NII at 14.05x.
On fundamentals, the company is posting revenue growth of 47.4%, a profit margin of 27.0%, return on equity of 41.3% in its most recent reported period.
Our data-driven engine currently flags this issue as a Neutral stance — the data is mixed and the risk-reward is balanced rather than one-sided. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Gaudium IVF IPO GMP — What It Means
The latest grey market premium for Gaudium IVF IPO is ₹-4 (-5.1%). GMP is an unofficial, dealer-quoted figure that hints at expected listing-day demand — it is not a guaranteed listing price. For Gaudium IVF it should be read alongside the subscription numbers and the company's fundamentals, since grey-market premiums can swing sharply during the bidding window.
See the full Gaudium IVF GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!